Companies announce strategic alliance Dec. 8 in which Toronto- based Novopharm will purchase 1,176,470 Deprenyl shares at an aggregate price of $3 mil. and will market and sell a generic version of Deprenyl's Eldepryl. Under the agreement, Deprenyl will market and sell multiple sclerosis, spinal cord injury and dermatology products in Canada for Novopharm after regulatory approval of the products. Novopharm will be granted 1,176,470 warrants for shares of Deprenyl common stock exercisable for up to four years at a base price of $2.70 per share. The warrant price escalates by 10% in the third and fourth years. Novopharm Chairman Leslie Dan will join the board of Deprenyl. Martin Barkin, president and CEO of Deprenyl, joins one of Novopharm's strategic committees.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth